Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Portfolio News / admin September 4, 2019 Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Read More »
Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer Portfolio News / admin September 3, 2019 Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer Read More »
Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy Portfolio News / admin August 14, 2019 Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy Read More »
ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance Portfolio News / admin August 8, 2019 ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance Read More »
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer Portfolio News / admin August 6, 2019 Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer Read More »
Escient Pharmaceuticals Appoints Kristin Taylor, PhD as Vice President and Head of Clinical Development Portfolio News / admin July 17, 2019 Escient Pharmaceuticals Appoints Kristin Taylor, PhD as Vice President and Head of Clinical Development Read More »
REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers Portfolio News / admin July 9, 2019 REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers Read More »
ORIC Pharmaceuticals Appoints Lori Friedman, PhD, as Chief Scientific Officer Portfolio News / admin July 9, 2019 ORIC Pharmaceuticals Appoints Lori Friedman, PhD, as Chief Scientific Officer Read More »
Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer Portfolio News / admin June 24, 2019 Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer Read More »
RAPT Therapeutics (Formerly FLX Bio) Completes $37 Million Series C Extension Portfolio News / admin June 18, 2019 RAPT Therapeutics (Formerly FLX Bio) Completes $37 Million Series C Extension Read More »